| scholarly article | Q13442814 |
| P50 | author | Johann de Bono | Q43249916 |
| David C. Smith | Q55965797 | ||
| John V Heymach | Q88721314 | ||
| P2093 | author name string | John Glaspy | |
| Ramesh K Ramanathan | |||
| Zev A Wainberg | |||
| Nicola J Curtin | |||
| Lauren Averett Byers | |||
| Rashmi Chugh | |||
| Miranda Patterson | |||
| Stan Kaye | |||
| Lida Mina | |||
| Saeed Rafii | |||
| Jasgit Sachdev | |||
| Ashleigh Herriott | |||
| Joshua W Henshaw | |||
| P2860 | cites work | PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies | Q27027503 |
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | Q27853235 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase | Q28511873 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| PARP inhibition: PARP1 and beyond | Q29619617 | ||
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
| Involvement of poly(ADP-ribose) polymerase in base excision repair | Q33601042 | ||
| Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? | Q33944812 | ||
| Role of poly(ADP-ribose) formation in DNA repair | Q34359946 | ||
| Whole genomes redefine the mutational landscape of pancreatic cancer | Q35911034 | ||
| Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer | Q37438981 | ||
| Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib | Q37623863 | ||
| The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. | Q37999166 | ||
| Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors | Q38262230 | ||
| Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage | Q39106841 | ||
| Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. | Q39282659 | ||
| Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval | Q39712677 | ||
| Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone | Q40220408 | ||
| Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer | Q42947764 | ||
| BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. | Q43755302 | ||
| Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). | Q47936662 | ||
| Accelerated titration designs for phase I clinical trials in oncology | Q73598986 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 620-629 | |
| P577 | publication date | 2017-02-27 | |
| P1433 | published in | Cancer Discovery | Q15724440 |
| P1476 | title | Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers | |
| P478 | volume | 7 |
| Q52430620 | A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. |
| Q92890485 | A decade of clinical development of PARP inhibitors in perspective |
| Q61866333 | A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) |
| Q90169827 | A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice |
| Q92702170 | Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options |
| Q57108063 | Advances in the use of PARP inhibitor therapy for breast cancer |
| Q52609131 | An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations. |
| Q89160515 | Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer |
| Q63884154 | BRCA2 and Other DDR Genes in Prostate Cancer |
| Q57810087 | Cell death in cancer in the era of precision medicine |
| Q38815964 | Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. |
| Q92697499 | Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer |
| Q47155297 | Current status of poly(ADP-ribose) polymerase inhibitors and future directions. |
| Q102210924 | DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition |
| Q90573547 | DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation |
| Q99583268 | Development of new medical treatment for epithelial ovarian cancer recurrence |
| Q92288309 | Enhancing Career Paths for Tomorrow's Radiation Oncologists |
| Q91865081 | Evidence to date: talazoparib in the treatment of breast cancer |
| Q64980046 | Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. |
| Q90916316 | Exploring and comparing adverse events between PARP inhibitors |
| Q89884126 | Familial Pancreatic Cancer: Current Perspectives |
| Q93068155 | Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma |
| Q91199443 | From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer |
| Q101237469 | Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer |
| Q64277715 | Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer |
| Q64389365 | Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer |
| Q48100807 | Germline genetic variants with implications for disease risk and therapeutic outcomes |
| Q60313365 | High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects |
| Q54965602 | How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. |
| Q90088006 | Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer |
| Q54977757 | Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis. |
| Q60146452 | Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data |
| Q91761588 | Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status |
| Q59795283 | Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review |
| Q64244918 | Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers |
| Q64940055 | Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer. |
| Q90216461 | Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies |
| Q90413979 | Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management |
| Q92486872 | Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets |
| Q89527853 | New Approaches to SCLC Therapy: From the Laboratory to the Clinic |
| Q91733148 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial |
| Q47549019 | Optimizing treatment in recurrent epithelial ovarian cancer |
| Q64913988 | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. |
| Q92164257 | PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca" |
| Q92257452 | PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development |
| Q89581160 | PARP and PARG inhibitors in cancer treatment |
| Q52585367 | PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. |
| Q89980735 | PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications |
| Q49723005 | PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer |
| Q50076626 | PARP inhibitors: Clinical utility and possibilities of overcoming resistance |
| Q93017366 | Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers |
| Q91620888 | Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer |
| Q90677069 | Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond |
| Q88148204 | Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma |
| Q91962793 | Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications |
| Q57105411 | Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer |
| Q90067362 | Precision medicine in pancreatic cancer: treating every patient as an exception |
| Q51747262 | Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation. |
| Q90320698 | Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study |
| Q64980716 | Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. |
| Q64387026 | Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era |
| Q57169452 | Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease |
| Q52628817 | Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors? |
| Q57793601 | State-of-the-art strategies for targeting the DNA damage response in cancer |
| Q93027996 | Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies |
| Q64058293 | Tailoring Ovarian Cancer Treatment: Implications of Mutations |
| Q57462253 | Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts |
| Q64235490 | Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors |
| Q90257629 | Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial |
| Q90101336 | Talazoparib: First Global Approval |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q91689195 | Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer |
| Q52657032 | Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. |
| Q60959613 | Targeting Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? |
| Q90750200 | Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer |
| Q47278103 | The development of PARP as a successful target for cancer therapy |
| Q41552673 | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. |
| Q38769421 | Unravelling the biology of SCLC: implications for therapy |
| Q52592609 | Update on PARP Inhibitors in Breast Cancer. |
| Q57111690 | Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer? |
Search more.